Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nektar and Baxter to develop therapeutics for hemophilia
Under the terms of the expanded agreement, Nektar will receive up to $44 million in upfront and milestone payments, funding of research and development, and manufacturing revenues during
Under the terms of the expanded agreement, Nektar will receive up to $44 million in upfront and milestone payments, funding of research and development, and manufacturing revenues during
The milestone payment arises from a drug discovery alliance with GSK to focus on the discovery of small-molecule TPO mimetics. Under the terms of the collaboration, Ligand is
Under the terms of the purchase agreement, the acquirer assumed all costs and liabilities of Solx as of December 1, 2007, in addition to a $5 million payment
The Phase II program is a multi-center, randomized, double-blind placebo- controlled study in patients with sleep maintenance insomnia (SMI). The primary endpoint is an assessment of objective slow
The authorization will allow commencement of the second clinical study for MultiStem, a proprietary stem cell product candidate, its first trial in the cardiovascular disease area. The Phase
In the new drug application (NDA), the company included results from two Phase III trials, one pivotal trial, and a supportive trial of Zentase in pediatric patients. Also
The open-label dose escalation trial in patients with progressive metastatic malignancies is currently ongoing at the H Lee Moffitt Cancer Center, Tampa, Florida, and at the M D
The clinical trial is a double-blind, placebo-controlled, multiple-dose trial lasting for four weeks followed by a voluntary open label period of up to eight additional weeks. The company
The patents were licensed from Southern Illinois University (SIU). The research underlying the patents was a collaboration of psychology faculty at SIU Carbondale and physiology and neurology faculty
Under this agreement, Emmaus will commercialize NutreStore, which is approved by the FDA for use in combination with human growth hormone as a treatment for short bowel syndrome